If you have a US drug and you are choosing a first market in Asia, the reflex is Japan, then Korea, then China. The reflex is wrong. For most US-originated assets the most logical first stop is Taiwan, and almost no one outside the region treats it that way.
I am here on a life-sciences trade mission hosted by TAITRA and Mosaic Venture Lab, representing the United States. Separately, I am also having meetings with BioPalace's investors and clients. Part of the job is to bring an American view on how a drug actually gets developed and paid for. Spend a few days asking how an asset moves through this market and the case for going here first stops being sentimental and starts being very practical.
The default, and what it costs
The default exists for good reasons. Japan is the second-largest drug market on earth. Korea is bigger than Taiwan and growing. China is the prize everyone eventually wants. So the Asia conversation starts with the big three, and Taiwan is treated as a follow-on you get to later.
The trouble is the entry cost. Japan still wants ethnic-sensitivity data and, in practice, months of PMDA pre-consultation before a trial starts; a realistic first-site activation runs to about eight months. Korea looks fast on paper, a 90 to 120-day review, but site activation and ethics review push a realistic trial start to roughly five and a half months. China is slower still, 14 to 20 months for a standard review, and it now carries a political tax that did not exist three years ago: draft US rules circulating in 2025 would put CFIUS review on American acquisitions of Chinese drug candidates and tighten FDA scrutiny of Chinese trial data. An asset built on a China-run trial can come home to a more skeptical FDA. Upon my return from the trip, I plan to write a detailed point of view on the state of the US-China evolving biopharmaceutical relationship.
Taiwan carries none of that. And it is faster at the one step that sets your whole clock: getting into the clinic.
Call it reliance, not reciprocity
Start with the thing people get wrong, including people who should know better. You will hear that Taiwan and the FDA have "reciprocity." They do not. There is no mutual-recognition agreement between Taiwan's TFDA and the FDA, in either direction. The FDA does not treat a Taiwanese approval as a shortcut into the US, and Taiwan does not rubber-stamp an FDA approval.
What Taiwan runs is foreign regulatory reliance, which is a more useful thing than the myth. TFDA leans on the assessment reports of trusted agencies to cut its own review, and it has built fast lanes around that idea. Two are worth knowing precisely, because the difference between them dictates your timeline.
The abbreviated review gives a new chemical entity a 180-day clock, half the standard 360, but only if the drug is already approved by two of three reference agencies: the FDA, the EMA, and Japan's PMDA. A US-only approval does not clear that bar. If you have FDA approval alone, which describes a lot of younger assets, you are on the priority track instead, which TFDA shortened in March 2025 from 300 to 240 days for drugs cleared by the FDA, EMA or Japan. So a single FDA approval buys you a 240-day review, and an FDA-plus-Europe or FDA-plus-Japan approval buys you 180. Either way you have skipped the Taiwan-specific bridging study that older guidance demanded.
The clinic is where the gap really becomes apparent. A standard trial application gets about 45 days at TFDA. File the same protocol simultaneously with the FDA or EMA, and the notification review drops to 14 calendar days, with the ethics review running in parallel. Nothing in Japan, Korea or China matches that for a US sponsor filing in step with its home agency. If your constraint is time to first patient, Taiwan is the fastest door in Asia.
Reimbursement: let's be honest about the gap
Here the boosters get ahead of the facts, so let me slow down. On reimbursement speed, Japan still wins. Japan lists a new drug for national reimbursement within 60 to 90 days of approval. Taiwan, historically, took more than a year, with a median lag in the better-studied cohorts somewhere between 378 and 458 days. If someone tells you Taiwan reimburses faster than Japan, they are wrong about standard drugs.
What has changed is the slope. Since January 2024 a manufacturer can file for a reimbursement recommendation in parallel with the marketing application rather than after it, and for qualifying drugs the insurer's target is coverage within six months of the license. Taiwan added a conditional listing route in 2023 for accelerated-approval drugs with immature data, and stood up a cancer drug fund in 2025 worth NT$5 billion, about $154 million a year, sitting outside the main insurance budget to cover new oncology drugs while evidence matures. The lag is closing for the assets most likely to come from a US pipeline. It has not closed yet, and I would not pretend it has.
The deeper point is that reimbursement speed is not why you go to Taiwan first. You go first for speed to data and proof, in a clean market, before you spend Japan money.
The advantage is access to hospitals
Taiwan's real asset is its clinical base. The island has more than 400 qualified medical institutions and over 140 recognized trial sites in a territory you can cross in an afternoon. National Taiwan University Hospital ran 141 CAR-T studies between 2020 and 2024 with five international partners, including phase III work. Two of the big centers are recognized by China's own regulator as reference sites, which tells you something about the quality bar.
The patient match is unusually good for a US oncology asset. Nearly half of Taiwan's trial applications in 2024 were in cancer, the national insurance covers almost all cancer care so patients do not drop out over cost, and the population carries a high rate of EGFR-mutated lung cancer, the target of a whole class of US drugs. AstraZeneca's ADAURA trial, which made adjuvant osimertinib standard of care, enrolled Taiwanese patients in its Asia cohort for exactly that reason. Trials here run 30 to 40 percent below US cost, protocols are accepted in English, and a central ethics system speeds multi-site work. In 2024 Taiwan also cut its first-in-human review from 120 days to 30 business days, opening a door for first-in-Asia phase I studies that did not exist before.
Prove value in Taiwan, expand further in Asia region
Put it together and the argument is not that Taiwan is the biggest Asian market. It plainly is not. The drug market is about $8.4 billion, a tenth of Japan's and a third of Korea's. Taiwan is a proving ground, and the case rests on speed, cost and a clean jurisdiction rather than the market size.
Prove value in one coherent market with the fastest clinical entry in the region, a credible regulatory path tied to your FDA work, and no China-decoupling exposure. Use the data and the listing to build the case for the larger markets next. The reflex tells you to plant your flag in the biggest room first. The schedule tells you to plant it where you can move fastest, and then scale.
One caveat before the close. Taiwan's intellectual-property regime is respectable for Asia, around 20th of 55 economies on the US Chamber's index, but it is not parity with the US or Europe, and there is a live dispute over how its patent-linkage rules treat dosage changes. Go in clear-eyed about that. It is a proving ground with real edges, not a utopia.
The questions to ask
So if you are a US drug developer weighing an Asia beachhead, three questions sort it quickly. Is your binding constraint time to first patient, or eventual revenue? If it is time, Taiwan wins on the clinic. Do you have FDA approval only, or FDA plus Europe or Japan? That single fact sets whether you are on the 240-day or the 180-day track. And is any part of your asset's history entangled with China in a way a US regulator or investor will have to unwind later? If so, a clean first market is worth more than a big one.
I came to Taipei to test whether the "front-door claim" survives contact with the people who move assets through this market. So far it is holding. I still think that for a US drug in Asia, that first door is in Taipei.